Profusa, Inc.

Profusa, Inc.

NNASDAQ:PFSA
0.41
USD
-0.04
(-9.44%)
-1,886.56EPS
1.54MMarket Cap
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-2,358.73
-4,625.26
-2,352.09
-2,111.64
-10,703.02
-1,886.56
Free Cash Flow per Basic Share
-2,445.89
-1,762.07
-1,007.55
-472.66
-4,856.89
-895.99
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
-19,138.87
-22,825.67
-25,164.95
-9,675.73
-2,163.8
-205.51
Tangible Book Value per Share
-19,138.87
-22,825.67
-25,164.95
-9,675.73
-2,163.8
-205.51
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
Depreciation Expense
1
1
- -
- -
- -
- -
Net Income, GAAP
-10
-20
-10
-9
-36
-43
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
Working Capital
-21
-35
-46
-57
-18
-27
LT Debt
8
- -
- -
- -
8
- -
Total Equity
-84
-100
-110
-119
-27
-27
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
7
13
14
LT Borrowings
8
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
10
1
2

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
4
1
1
Cash, Cash Equivalents & STI
2
- -
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
22
29
28
Payables & Accruals
11
12
10
ST Debt
7
13
14
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-77.64%
Free Cash Flow
- -
- -
686.83%
Net Income, GAAP
- -
- -
288.11%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-545.64
-90.94
-571.27
-8,713.6
-2,111.64
2025
-621.37
-537.18
-5,246.34
-695.33
-10,703.02
2026
-204.73
-151.8
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Jack E. Stover
Full Time Employees
2
Sector
Finance
Industry
Financial conglomerates
Address
626 Bancroft Way, Suite A Berkeley CA United States 94710
IPO Date
Jul 14, 2025
Business
Profusa, Inc. is a digital health innovator engineering advanced tissue-integrated biosensors to consistently track an individual's internal body chemistry, delivering intelligent, data-driven health insights for managing long-term conditions. The company's Lumee™ Oxygen Platform, which has received CE Mark approval for European use, employs micro-sensors and optical readers to provide real-time tissue oxygen levels, addressing needs in peripheral artery disease, chronic wounds, and reconstructive surgery. Profusa is also progressing toward a continuous glucose monitoring system for diabetes management, aiming to harness AI for personalized medical data directly from within the body to inform treatment and improve outcomes.

Company News

  • Profusa Announces Progress Towards Satisfying the Conditions to Close of the Option Agreement with G3

  • Profusa, Inc. (NASDAQ:PFSA) Stock Short Interest Report for October

  • Profusa Receives ISO 13485:2016 Certificate from GMED

  • Head to Head Review: OraSure Technologies (NASDAQ:OSUR) and Profusa (NASDAQ:PFSA)

  • Micro Cap Profusa Navigates European Regulatory Hurdles to Advance Oxygen Monitoring Tech

  • Profusa Announces Significant Progress Towards Lumee® Oxygen Platform CE Mark with ISO 13485 Certification Expected in Early October

  • Profusa, Inc. Receives Nasdaq Compliance Determination

  • Profusa, Inc. Announces Compliance with Nasdaq Publicly Held Shares Requirement

  • Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company

  • Profusa Announces 1-for-4 Reverse Stock Split

  • Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs

  • Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company

  • Profusa Announces 1-for-25 Reverse Stock Split

  • Profusa Shareholders Approve Strategic Initiatives at 2026 Annual Meeting, Supporting PanOmics Acquisition, Balance Sheet Strengthening and Nasdaq Compliance Efforts

  • Profusa Shareholders Approve Strategic Initiatives at 2026 Annual Meeting, Supporting PanOmics Acquisition, Balance Sheet Strengthening and Nasdaq Compliance Efforts

  • Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform

  • Profusa Issues Letter to Shareholders Encouraging Shareholders to Vote FOR All Proposals at June 23, 2026 Annual Meeting

  • Profusa Announces Listing Transfer to The Nasdaq Capital Market

  • Profusa Receives Favorable Nasdaq Listing Determination

  • Profusa Receives Favorable Nasdaq Listing Determination